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 Introduction 
 The lower gastrointestinal tract of mammals is inhab-
ited by a very dense and diverse bacterial microflora that 
exists in a state of mutualism with the host. A constant 
molecular dialogue between the microbiota and the host 
is required for the establishment and maintenance of in-
testinal homeostasis. Dysregulated immune responses to 
the commensal microbiota and accompanying intestinal 
inflammation occur directly as a loss of equilibrium be-
tween finely tuned pro- and anti-inflammatory mecha-
nisms within the gastrointestinal tract   [1, 2] .  Although 
the intestinal mucosa is populated by a number of spe-
cialized lymphocyte populations that mediate diverse 
immune responses to gut pathogens and commensals, 
these adaptive responses are elicited following sensing of 
microbial or environmental factors by innate immune 
cells. The importance of innate immune pathways in in-
testinal homeostasis is underscored by genome-wide as-
sociation studies that have identified polymorphisms in 
many innate immunity genes that influence susceptibil-
ity to inflammatory bowel disease (IBD)   [3]  . The innate 
immune compartment in the gut encompasses many in-
nate leucocyte populations, as well as several types of in-
testinal epithelial cells (IEC), which act together to main-
tain a balanced immune response to the microbiota. 
Here, we review the key roles of innate immune activa-
tion in the gut, including maintenance of homeostasis 
during steady state, restoration of the epithelium follow-
ing insult or injury, and induction of protective and 
pathogenic inflammatory responses.
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 Abstract 
 Loss of intestinal immune regulation leading to aberrant im-
mune responses to the commensal microbiota are believed 
to precipitate the chronic inflammation observed in the gas-
trointestinal tract of patients with inflammatory bowel dis-
eases (IBD), Crohn’s disease and ulcerative colitis. Innate im-
mune receptors that recognize conserved components
derived from the microbiota are widely expressed by both 
epithelial cells and leucocytes of the gastrointestinal tract 
and play a key role in host protection from infectious path-
ogens; yet precisely how pathogenic and commensal mi-
crobes are distinguished is not understood. Furthermore, 
aberrant innate immune activation may also drive intestinal 
pathology, as patients with IBD exhibit extensive infiltration 
of innate immune cells to the inflamed intestine, and poly-
morphisms in many innate immunity genes influence sus-
ceptibility to IBD. Thus, a balanced interaction between the 
microbiota and innate immune activation is required to 
maintain a healthy mutualistic relationship between the mi-
crobiota and the host, which when disturbed can result in 
intestinal inflammation.    Copyright © 2011 S. Karger AG, Basel 
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    IEC Intrinsic Pattern Recognition Receptor 
Activation Regulates Intestinal Homeostasis 
  The intestinal epithelium consists of a single layer of 
columnar epithelial cells that provide an effective physi-
cal barrier separating the vast bacterial load of the intes-
tinal flora from cells of the host immune system. The 
continuous crypts and villi that make up the intestinal 
epithelium possess several physical, biochemical and im-
munological mechanisms ensuring intestinal homeosta-
sis, i.e. mutualistic interactions with commensal mi-
c r o b e s  c o n tr a s t e d  b y  p r o t e c ti v e  i m m u n i ty  t o  i n v a s i v e  
pathogens. Actin-rich microvillar protrusions from the 
apical IEC surface form a mechanical brush border, 
which, in combination with goblet cell-secreted mucins, 
comprise a sterile barrier that is impermeable to most in-
testinal microbes. The mucus layer of the intestine con-
sists of an inner glycocalyx of membrane-anchored mu-
cins, covered by an outer layer of secreted mucins, which, 
in addition to being a viscous barrier to microbes, forms 
a matrix loaded with high concentrations of IEC-derived 
antimicrobial peptides and secretory IgA.
    IEC are permanently in contact with the intestinal lu-
men contents and, therefore, ideally located to undertake 
immunosurveillance of commensal and pathogenic pop-
ulations within the intestinal microbiota. Microbe-asso-
ciated molecular pattern triggering of pattern recogni-
tion receptors (PRR) classically drives a nuclear factor-  B 
(NF-   B)-dependent pro-inflammatory response and ini-
tiation of both innate and adaptive immune responses to 
the invading microbe. Triggering of PRR signalling with-
in IEC is critical for a broad spectrum of host-protective 
responses to pathogenic species in the intestine, includ-
ing enhanced production of cytokines, chemokines and 
induction of B-cell class switch recombination for the 
production of secretory IgA   [4]  . In order to discriminate 
between commensal and invasive pathogenic bacteria, 
IEC display compartmentalized expression of Toll-like 
receptors (TLR), as well as differential regulation of tran-
scription networks in response to TLR ligands   [4]  . It is 
now well recognized that under steady state conditions, 
sensing of the microbiota and basal PRR signaling in IEC 
is important for intestinal homeostasis and constant re-
newal of the epithelial barrier. IEC intrinsic TLR trigger-
ing maintains immune pressure on the commensal flora 
through production of broad-spectrum anti-microbial 
peptides (AMP) that are able to limit both colonization 
and translocation of commensal and pathogenic species 
  [4]  . In addition, following infection or insult, IEC intrin-
sic PRR signalling promotes epithelial renewal, restitu-
tion and tight junction fortification by driving expression 
of anti-apoptotic and proliferative genes   [4]  . Acute intes-
tinal inflammation observed in the dextran sodium sul-
phate (DSS) colitis model arises due to a loss of epithelial 
integrity and disruption of barrier function between the 
intestinal microbiota and lamina propria immune cells. 
This triggers a potent inflammatory response mediated 
primarily by innate leucocytes, followed by restitution 
and repair of the epithelial barrier. Early studies using the 
DSS colitis model found that genetic deficiency in TLR4 
or MyD88 resulted in increased IEC apoptosis and more 
severe intestinal pathology, demonstrating a cell autono-
mous role for TLR signalling in IEC proliferation and in-
tegrity. These protective functions are not only depen-
dent on sensing of the microbiota by TLR because recent 
studies demonstrated that similar responses were elicited 
by activation of cytosolic Nod-like receptor (NLR) sig-
nalling pathways in IEC. Thus, mice deficient in NLRP3, 
or the associated adaptor ASC, or the inflammasome ef-
fector caspase-1, exhibited hyper-susceptibility to acute 
DSS colitis, with increased histopathological damage, el-
evated chemokine levels and leucocyte infiltration that 
was accompanied by increased systemic dispersion of 
commensal bacteria   [5, 6]  . Both NLRP3 and caspase-1 
deficiency resulted in significantly decreased IEC prolif-
eration and turnover during acute colitis, and bone mar-
row chimera experiments demonstrated that genetic de-
ficiency in NLRP3 in the intestinal epithelium was the 
major factor responsible for the exacerbated disease phe-
notype   [5, 6]  . The protective effects of NLR signalling in 
IEC during DSS colitis were associated with the produc-
tion of interleukin (IL)-18, a cytokine that is secreted fol-
lowing NLR-mediated activation of caspase-1  [5, 6] . Con-
sistent with these findings, a polymorphism in the hu-
man  NLRP3  gene that leads to reduced NLRP3 expression 
was identified as a risk allele for Crohn’s disease (CD)  [7] .
  Mutations  in   NOD2 (CARD15),   which encodes the cy-
tosolic NLR NOD2 that detects the bacterial peptidogly-
can derivative muramyl dipeptide (MDP), have long been 
associated with susceptibility to CD, but the mechanisms 
responsible remain unclear   [8]  . NOD2 signalling in my-
eloid cells has been reported to attenuate inflammatory 
responses induced by TLR and may also limit IL-1     se-
cretion, suggesting that constitutive detection of MDP by 
myeloid cells may dampen pro-inflammatory responses 
in the gut   [8]  . However, several lines of evidence suggest 
that intrinsic NOD2 signals also play an important role 
in IEC homeostasis. NOD2 has been linked to the secre-
tion of     -defensins by Paneth cells in the small intestine, 
and administration of MDP has been reported to protect   Innate Immune Activation in the Gut  J Innate Immun 2011;3:585–593 587
against experimental colitis in mice  [8] . Moreover, recent 
studies have identified a link between NOD2 and autoph-
agy, a conserved catabolic pathway in which cytoplasmic 
contents are targeted for degradation in lysosomal com-
partments. Autophagy is upregulated in response to star-
vation, stress or infection and may play an important role 
in defence against intracellular bacteria. Polymorphisms 
in autophagy genes, such as   IRGM  and   ATG16L1,  have 
been associated with susceptibility to CD   [3]  , and it was 
recently reported that activation of NOD2 could stimu-
late autophagy and that NOD2 directly facilitated the re-
cruitment of ATG16L1 to sites of bacterial entry at the 
plasma membrane   [9, 10]  . Furthermore, autophagy is 
closely linked to endoplasmic reticulum (ER) stress and 
the consequent induction of the unfolded protein re-
sponse. The highly secretory nature of many IEC makes 
them pre-disposed to ER stress, and polymorphisms in 
ER stress genes are associated with IBD   [11]  . Taken to-
gether, these findings suggest that PRR, ER stress and
autophagy circuits function in an integrated manner to 
regulate bacterial handling in the intestinal epithelium 
  [2, 11] .
  N F -    B signalling within both IEC and haematopoi-
etic cell compartments is fundamental to the mainte-
nance of intestinal homeostasis. Appropriate pro-in-
flammatory stimuli initiate signalling cascades ultimate-
ly resulting in I    B kinase (IKK) complex-dependent 
activation and nuclear translocation of NF-   B  subunit 
heterodimers that drive gene transcription. Selective dis-
ruption of homeostatic NF-    B signalling within IEC, by 
targeted ablation of the IKK regulatory subunit NEMO 
(NEMO  IEC-KO  ) or of both IKK-catalytic subunits IKK    
and IKK    , led to spontaneous IEC apoptosis and severe 
intestinal inflammation   [12] .  NEMO IEC-KO   mice exhib-
ited reduced AMP secretion from IEC resulting in in-
creased levels of commensal bacteria crossing the epithe-
lial barrier to the lamina propria. In addition, IEC in 
NEMO  IEC-KO  mice were hypersensitive to tumor necrosis 
factor (TNF)-  -induced apoptosis and genetic ablation of 
TNFR1-ablated intestinal inflammation   [12] .  Similarly, 
mice rendered specifically deficient in RelA or IKK     in 
IEC exhibited increased susceptibility to chemically in-
duced colitis   [13]  . Recent evidence indicates that the NF-
    B target gene A20 (TNFAIP3), which has been associ-
ated with CD, plays a key role in preventing excessive 
apoptosis of IEC, as mice with selective ablation of A20 
in IEC exhibited increased susceptibility to DSS colitis 
and to TNF-    -triggered apoptosis   [14]  . Another impor-
tant anti-inflammatory circuit induced by NF-  B signal-
ling in IEC is the secretion of the epithelial cytokine thy-
mic stromal lymphopoietin (TSLP). Microbiota sensing 
by IEC elicits IKK    -dependent production of TSLP that 
plays a key role in conditioning local dendritic cell (DC) 
populations within the intestine that in turn regulate the 
type and magnitude of effector T-cell responses in the gut 
  [15]  . The range of intestinal microbes that manipulate 
these pathways further illustrates the importance of NF-
    B signals in regulating intestinal homeostasis. Patho-
genic bacteria and viruses exhibit an expansive repertoire 
of microbial mechanisms aimed at immune subversion 
by perturbation/activation of NF-    B signalling. Com-
mensal microbes may also inhibit efficient transduction 
of NF-    B signals in order to temper or avoid inflamma-
tory responses. For example, enhanced nuclear export of 
the active NF-    B subunit RelA in complex with peroxi-
some proliferator-activated receptor-   drives the anti-in-
flammatory activity of the human anaerobic commensal 
  Bacteroides thetaiotaomicron   [16]  . Taken together, these 
findings indicate that numerous synergistic mechanisms, 
both host and microbe mediated, ensure that tonic levels 
of intrinsic PRR signalling occur constitutively in IEC 
and that this maintains epithelial integrity and turnover, 
regulates the composition and penetrance of the micro-
biota, and prevents overt inflammation in response to 
commensals.
    Myeloid Cells Regulate Immune Responses in the 
Healthy and Inflamed Gut 
  Intestinal antigen-presenting cells (APC) comprise 
heterogeneous cell populations that are present within 
the organized gut-associated lymphoid tissue, including 
Peyer’s patches, isolated lymphoid follicles and draining 
mesenteric lymph nodes (MLN) and the lamina propria. 
Recent advances have described differences in ontogeny, 
phenotype and tissue location that relate to functionally 
distinct populations of intestinal myeloid cells, which en-
compass DC, monocytes and macrophages   [17]  . As re-
viewed elsewhere within this issue  [18] , intestinal macro-
phages have many adaptations to prevent overt inflam-
matory responses to the microbiota under homeostatic 
conditions; therefore, we shall mainly focus on effector 
functions of intestinal myeloid cells. Differential expres-
sion of fractalkine receptor CX3CR1 and integrin sub-
unit CD103 identifies two major populations of intestinal 
myeloid cells that have been implicated in tolerance path-
ways in the intestine. CD11b  +  CD103 +  lamina propria DC 
derive from pre-classical DC lineage, whereas CD11c  +  
CX3CR1  +   mononuclear phagocytes (MP) may constitute  Harrison/Maloy
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a more heterogenous population of DC and macrophages 
tha t ste m fr o m L y -6C   +   monocytes under homeostatic 
conditions   [17] .
  Microbiota-dependent signals drive CD11c  +  CX3CR1 +  
MP accumulation in the lamina propria adjacent to the 
IEC layer   [19]  . Expression of tight junction proteins by 
CX3CR1  +   MP allows projection of transepithelial den-
drites in order to sample luminal contents, and this pro-
cess has been suggested to contribute to resistance to en-
teric pathogens, such as   Salmonella typhimurium.   How-
ever, CD11c  +   CX3CR1 +   MP appear not to traffic to the 
draining MLN or prime naïve T cells, and the defective 
induction of systemic immune tolerance to dietary anti-
gen (oral tolerance) observed in CX3CR1-deficient mice 
instead supports a role for CX3CR1  +   MP in enhancing 
tolerogenic immune responses in the gut   [20] .  Impaired 
induction of oral tolerance was associated with a failure 
to expand lamina propria FoxP3  +   T reg   cells and with re-
duced production of the anti-inflammatory cytokine IL-
10 by intestinal myeloid cells   [20]  . An important role for 
myeloid cell-derived IL-10 in the regulation of intestinal 
immune responses was further supported by an indepen-
dent report that an innate source of IL-10 was required 
for maintenance of FoxP3 expression and control of ex-
perimental colitis by FoxP3  +   T reg   cells   [21]  . Thus, al-
though FoxP3  +  T reg  cells could suppress colitis induced by 
adoptive transfer of naïve CD4  +   T cells into Rag  –/–   recip-
ients, they were unable to prevent colitis induction in 
Rag  –/–   IL-10 –/–   recipients   [21]  . Innate IL-10 secretion by 
CD11b  +   CD11c +   F4/80 +   myeloid cells was necessary to 
maintain FoxP3 expression and suppressive functions of 
T  reg   cells in the inflamed intestine   [21] .
    In contrast to the sub-epithelial localization of
CX3CR1  +  MP, the anatomical location of CD11b  +  CD103 +  
DC is more varied, with populations dispersed both 
throughout the gut-associated lymphoid tissue and lam-
ina propria   [20]  . Small intestinal lamia propria CD103  +  
DC perform typical DC sentinel functions; they can 
sense and take up a wide variety of foreign bacteria and 
innocuous antigens and migrate to the draining MLN 
where they initiate adaptive immune responses with an 
intestinal tropism, such as imprinting of the gut-homing 
receptors CCR9 and     4    7   on activated T cells and induc-
tion of intestinal B-cell class switch to IgA production  [17, 
20, 22]  . These activities are dependent on retinoic acid 
(RA), a dietary metabolite derived from vitamin A, and 
CD103  +   lamina propria DC express   aldh1a1  and   aldh1a2 
  genes that encode for retinal metabolizing enzymes re-
quired for RA synthesis   [22] .  CD103 +   DC play an impor-
tant role in inducing tolerance to intestinal antigens un-
der steady state conditions, as they migrate to the MLN 
and promote the generation of FoxP3  +  inducible T  reg  cells 
through a transforming growth factor (TGF)-     and RA-
dependent mechanism   [22]  . Interestingly, recent evi-
dence indicates that distinct myeloid cell compartments 
may co-operate to maintain intestinal tolerance as robust 
oral tolerance was associated with further expansion of 
gut-homing FoxP3  +  T reg  cells in the intestinal lamina pro-
pria through interactions with CX3CR1  +   MP   [23] .  Taken 
together, these findings highlight that a number of het-
erogeneous subsets of myeloid cells can participate in the 
maintenance of immune tolerance in the gut (  fig. 1  a).
    Myeloid cells, granulocytes and innate lymphoid cells 
(ILC) all accumulate within the intestine during chronic 
intestinal inflammation and contribute to the excessive 
production of pro-inflammatory mediators that drive in-
testinal pathology   [1, 2]  . In contrast to the protective ef-
fects of ‘tonic’ PRR signals in IEC described above, sev-
eral studies have reported that persistent PRR signals in 
leucocyte populations are crucial for the induction and 
perpetuation of chronic intestinal inflammation. For
example, the microbiota-dependent spontaneous colitis 
that develops in IL-10  –/–   mice was completely absent in 
IL-10  –/–   MyD88 –/–   mice, and genetic ablation of MyD88 
also rescued the spontaneous colitis phenotype of mice 
harbouring an IEC-specific deletion of the IKK-regulato-
ry subunit NEMO   [12]  , suggesting that functional TLR 
signals were required for intestinal inflammation. In ad-
dition, the innate immune-meditated typhlocolitis that 
develops following infection of Rag  –/–   mice with the 
Gram-negative intestinal bacterium   Helicobacter hepati-
cus   was completely abrogated in Rag  –/–   MyD88 –/–   mice 
  [24]  . Furthermore, bone marrow chimeric Rag  –/–   mice in 
which MyD88 signalling was selectively absent in haema-
topoietic cells were also completely resistant to   H. hepat-
icus  -induced intestinal pathology, indicating a specific 
requirement for this signalling pathway in leucocytes 
  [24]  . Similarly, selective IKK     deficiency in myeloid cells 
(LysM  Cre    !   IKK   flox/flox  ) ameliorated intestinal inflam-
mation in the IL-10  –/–   model of spontaneous colitis, 
whereas IEC-specific deletion of IKK     (Villin Cre    ! 
IKK    flox/flox ) did not ameliorate the disease in this setting 
  [13]  . In other T-cell colitis models, it was shown that T-
cell intrinsic MyD88 signals were not essential for the in-
duction of intestinal pathology  [24] ; however, MyD88 sig-
nals in DC were required for the induction of pathogenic 
T-cell responses in the gut   [25]  . Together, these studies 
strongly support a crucial role for MyD88 signalling in 
myeloid cells in driving innate and adaptive inflamma-
tory responses in the gut. During ongoing inflammation,   Innate Immune Activation in the Gut  J Innate Immun 2011;3:585–593 589
populations of intestinal myeloid APC develop pro-in-
flammatory characteristics that exacerbate immune-me-
diated pathology. Intestinal inflammation abrogates the 
tolerogenic activities of CD103  +  MLN DC, with decreased 
expression of   aldh1a2  and   tgf    2   correlating with an in-
ability to promote FoxP3  +   T reg   responses   [26] .  Instead, 
under inflammatory conditions, CD103  +   DC produce 
significantly more IL-6 than their steady state counter-
parts and promote the emergence of Th1 cells   [26] .  Simi-
larly, flagellin-mediated activation of CD103  +   lamina 
propria DC through TLR5 promotes the generation of 
Th17 cells   [27]  . Furthermore, a CD70  Hi   CX3CR1 +   subset 
of intestinal APC can detect microbiota-derived ATP 
through purinergic P  2  X and P  2  Y receptors, resulting in 
the up-regulation of molecules associated with Th17 lin-
eage commitment, including IL-6, IL-23 and the TGF-  -
activating integrin     V    8    [28]  . The same study reported 
that administration of an A TP analogue led to an in-
crease in frequency of colonic Th17 cells in germ-free an-
imals and also exacerbated T-cell transfer colitis, suggest-
ing a role for intestinal myeloid cells in driving colonic 
Th 1 7  g e n e r a ti o n  un d e r  infl amm a t o ry  c o n di ti o n s    [28] . 
Mouse models of colitis suggest that the altered pheno-
typic and functional properties of myeloid cells in the in-
flamed intestine may partly reflect the accumulation of 
newly recruited cells, particularly monocyte-derived MP 
that respond to TLR stimulation by the elaboration of 
pro-inflammatory cytokines  [17] . These observations are 
consistent with findings that intestinal tissues from CD 
patients exhibit infiltration by a population of CD14  +   in-
flammatory monocytes that produce elevated levels of IL-
23, TNF-     and IL-6   [29]  . A better understanding of how 
inflammatory myeloid cells are recruited and activated in 
the intestine may facilitate new therapeutic approaches in 
IBD.
    Innate Immune Cytokine Networks Drive Intestinal 
Pathology 
 A large body of clinical and experimental evidence im-
plicates innate leucocytes, especially myeloid cells, as 
critical sources of a range of inflammatory cytokines in 
the inflamed intestine   [1]  . These may exacerbate patho-
logical responses in several ways: through effects on tis-
sue stromal cells and IEC, through stimulation of inflam-
matory responses from other innate leucocytes, or 
through the induction of pathogenic effector T-cell re-
sponses  ( fig. 1 b).
    Blockade or neutralization of these factors constitutes 
an important new therapeutic approach, as exemplified 
by the successful application of anti-TNF-   antibodies in 
ab
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  Fig. 1.   Innate immune circuits control in-
testinal homeostasis.  a  During steady state 
conditions, a number of specialized my-
eloid cell populations act in concert with 
IEC and dietary metabolites such as RA to 
promote tolerance to luminal antigens.
  b   In IBD, there is a dramatic alteration in 
the composition and functions of myeloid 
cells in the intestinal lamina propria. They 
produce elevated levels of inflammatory 
cytokines that drive the activation of ad-
ditional populations of innate and adap-
tive leucocytes, resulting in chronic in-
fl a m m a t o r y  p a t h o l o g y .  T S L P  =  T h y m i c  
stromal lymphopoietin; sIgA = secretory 
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IBD patients   [1]  . Immunohistochemical studies identi-
fied lamina propria macrophages as a key source of TNF-
     in the inflamed gut, although other cells including Pa-
neth cells and Th1 cells may also produce TNF-      [1] . 
TNF-     signalling can modulate a broad range of cellular 
responses in both haematopoietic cells and parenchymal 
cells, including cellular activation and proliferation, as 
well as potent effects on IEC integrity and apoptosis. Ge-
netic ablation or antibody-mediated blockade of TNF-    
has been shown to reduce or ameliorate intestinal pathol-
ogy in a wide range of mouse models of IBD, indicating 
that it is a central factor in intestinal inflammation   [1] . 
Treatment with anti-TNF-   can restore intestinal barrier 
function in IBD patients and this has been ascribed to 
reduced apoptosis of IEC together with induction of 
apoptosis of lamina propria mononuclear cells express-
ing membrane-bound TNF-      [1] .
    IL-6 is another classical pro-inflammatory cytokine 
that is elevated in the inflamed intestinal mucosa of IBD 
patients and is predominantly produced by innate leuco-
cytes in the lamina propria   [30]  . IL-6 can signal both in 
  cis-  , through membrane-bound IL-6R, and in   trans- , 
through soluble IL-6R (sIL-6R)/IL-6 complex binding to 
membrane-associated gp130. Thus, as gp130 is widely ex-
pressed, IL-6 potentially affects a broad range of cell types, 
which may have complex effects on intestinal homeosta-
sis. For example, IEC express the IL-6R, and binding of 
IL-6 may trigger cytoprotective NF-    B activation in IEC. 
By contrast, increased levels of IL-6 in the inflamed mu-
cosa may exacerbate inflammation in several ways, such 
as induction of additional inflammatory mediators from 
macrophages and by promoting the differentiation and 
survival of pathogenic Th1 and Th17 cells   [1, 30] .  Consis-
tent with a dominant pathogenic role of IL-6 in IBD, ben-
eficial effects were reported in a pilot trial of an anti-IL-6R 
antibody in patients with active CD   [1] .
    Recent findings linking genetic mutations associated 
with secretion of the cytokines IL-1   and IL-18 with IBD 
susceptibility have rekindled interest in their roles in in-
testinal homeostasis. Upon activation by infection or 
stress, several cytosolic NLR are able to form multi-mo-
lecular platforms, termed ‘inflammasomes’, that drive 
auto-catalytic activation of caspase-1, a cysteine protease 
required for processing of pro-IL-1     and pro-IL-18 to 
their secreted active forms. Polymorphisms in NLRP3, 
IL-18 and IL-18RAP have all been associated with suscep-
tibility to IBD   [1]  , and both IL-1     and IL-18 expression 
are increased in inflamed IBD tissues   [31, 32] .  Interest-
ingly, myeloid cells lacking the IBD risk-associated au-
tophagy gene  Atg16l1  produced increased amounts of IL-
1    and IL-18, suggesting that a functional autophagy 
pathway may limit inflammasome activation. Levels of 
IL-1     are elevated in models of intestinal inflammation 
and blockade of IL-1     signalling, using anti-IL-1     or, by 
administration of the natural antagonist IL-1ra, can ame-
liorate the disease   [1, 31] .
  I L -1   is secreted primarily from monocytic cells in the 
lamina propria and promotes activation of myeloid cells 
as well as neutrophilia and neutrophil migration into in-
flamed tissues   [31] .  IL-1    can also enhance pathogenic 
adaptive responses, particularly Th17 cell responses  [33] . 
IL-18 levels are increased in several models of colitis and 
antibody-mediated neutralization of IL-18, or adminis-
tration of the natural antagonist IL-18BP can reduce in-
testinal pathology  [32] . In the chronically inflamed intes-
tine of IBD patients, IL-18 is predominately associated 
with mononuclear leucocytes in the lamina propria, 
where it may contribute to disease progression through 
promotion of Th1 responses  [32, 33] . However, the role of 
IL-18 in intestinal homeostasis is complex because, as 
noted earlier, NLR activation has been associated with 
protective responses in IEC. Indeed, production of IL-18 
within the healthy gastrointestinal tract appears restrict-
ed to the intestinal epithelium   [32]  , and administration 
of exogenous IL-18 protected NLRP3-deficient mice from 
exacerbated pathology during DSS colitis, suggesting an 
IEC-intrinsic role for IL-18 in intestinal epithelial ho-
meostasis  [5, 6] . Similarly, genetic deficiency in either IL-
18 or IL-18R renders mice more susceptible to DSS colitis 
  [32]  . Thus, depending on the cellular location and tem-
poral characteristics of activation, inflammasome-de-
pendent cytokine responses may have beneficial or harm-
ful effects on intestinal homeostasis   [32] .  Following
epithelial damage, IL-18 signalling in the intestinal epi-
thelium plays a key role in maintaining epithelial integ-
rity, by promoting restitution and repair pathways in 
IEC. Conversely, chronic excessive production of IL-1    
and IL-18 by lamina propria mononuclear cells may con-
tribute to the deleterious inflammatory responses ob-
served in IBD patients. Additional studies on inflamma-
some activation in the gut may offer further insights into 
IBD pathophysiology.
    IL-23 Drives Conserved Cytokine Circuits in 
Intestinal Inflammation 
  Genome-wide association studies associating poly-
morphisms in the IL-23R and IL-12p40 with susceptibil-
ity to CD, together with experimental studies showing   Innate Immune Activation in the Gut  J Innate Immun 2011;3:585–593 591
that removal or blockade of IL-23 could ameliorate chron-
ic colitis, have highlighted IL-23 as a central regulator of 
intestinal homeostasis and inflammation   [1, 2] .  Produc-
tion of IL-23 in the intestine is induced by PRR stimula-
tion of myeloid cells, and DC appear to be a key source of 
IL-23 both during steady state conditions and also in the 
inflamed intestine  [34] . In addition, a population of CD14 +  
intestinal macrophages from the gut of CD patients have 
been reported to secrete large amounts of IL-23  [29] . IL-23 
can drive intestinal pathology through excessive activa-
tion of innate and adaptive inflammatory responses  [1, 2] . 
IL-23 drives T-cell-dependent intestinal inflammation 
through direct signalling into CD4  +   T cells to drive the 
proliferation and accumulation of effector Th1 and Th17 
cells in the gut, as well as by promoting the emergence of 
a population of IL-17A  +   interferon (IFN)-    +   CD4 +   T cells 
and restraining the differentiation of Foxp3  +   T reg   cells 
  [34] . A population of CD161  +  CD4 +  T cells able to respond 
directly to IL-23 stimulation with production of both IL-
17A and IFN-   has also been identified in the lamina pro-
pria of patients with IBD  [35] . In addition to CD4  +  T cells, 
several populations of innate leucocytes are able to pro-
duce IL-17A, IL-22 and IFN-     in response to IL-23. For 
example,        T cells are enriched among the intestinal ep-
ithelial lymphocytes and can respond to IL-23 and IL-1    
by secretion of IL-22 and IL-17A   [36]  . However, although 
       T cells have been shown to drive intestinal inflamma-
tion in some experimental models  [37] , their contribution 
to IBD remains unclear. Recent studies from several 
groups have identified multiple populations of novel ILC 
that are present in the gut and have been implicated in in-
testinal homeostasis, inflammation and host protection 
  [38]  . The ontogeny of different ILC populations is dis-
cussed elsewhere in this issue   [39] , but many appear to 
derive from a common ROR   t +   precursor that is depen-
d e n t u po n bo th cyt o kin e an d co mm e nsal bact e ria -d e-
rived signals for further lineage commitment   [38] .  Using 
a mouse IBD model in which infection of   Rag2  –/–   mice 
with   H. hepaticus   drives an IL-23-dependent innate im-
mune-mediated typhlocolitis, we identified a novel popu-
lation of CD4–ROR   t +   Thy1 Hi   Sca-1 +   ILC that accumu-
lated in the inflamed intestine and secreted IL-17A, IL-22 
and IFN-     in response to IL-23   [40]  . Furthermore, neu-
tralization of either IL-17A or IFN-     significantly attenu-
ated colitis, and depletion of ILC using anti-Thy1 com-
pletely abrogated intestinal inflammation   [40] .
    Although IL-17A is greatly increased in the intestinal 
mucosa of IBD patients, experimental models have gen-
erated conflicting evidence over whether it primarily acts 
as a pro- or anti-inflammatory factor in the gut  [1, 2] . For 
example, IL-17A appears to have a protective role in acute 
DSS colitis whereas it appears to have a pro-inflammato-
ry role in trinitrobenzene sulfonic acid colitis  [1, 2] . Again, 
these discrepancies may reflect differences in the location 
and temporal characteristics of IL-17A secretion, as well 
as in differential activities of IL-17 A depending on the 
presence or absence of other cytokines in the local micro-
environment. The pro-inflammatory effects of IL-17A 
have been related to the induction of cytokines and che-
mokines from tissue cells, such as epithelial and endothe-
lial cells, which in turn promotes the recruitment and 
activation of neutrophils   [2]  . By contrast with the am-
biguous activities of IL-17A, the pro-inflammatory ef-
fects of IFN-     in the intestine have been firmly estab-
lished by the disease-attenuating effects of removal or 
blockade of IFN-     in experimental models of chronic 
colitis  [1] . In the inflamed intestine, IFN-  -secreting cells 
are far more prominent than those producing IL-17A, and 
IFN-    may exert pro-inflammatory effects by directly in-
fluencing IEC turnover and epithelial integrity and by 
activating macrophages in the lamina propria   [1, 2] . Nev-
ertheless, the disappointing efficacy of IFN-   blockade in 
human IBD suggests that there is a complex interplay be-
tween ‘Th1’ and ‘Th17’ cytokine responses in the gut and 
that therapies targeting both axes may be required to ef-
fectively combat chronic intestinal pathology.
    Finally, IL-23 is also a potent driver of IL-22, an IL-10 
family member that acts to enhance innate immune de-
fences in mucosal tissues   [41]  . Restricted to expression in 
the non-haematopoietic system, the IL-22R is highly en-
riched on mucosal epithelial cells, especially those of the 
skin, lung and gut   [41]  . In IEC, IL-22 signalling contrib-
utes to intestinal homeostasis by activation of ST A T3, 
which enhances epithelial healing and regeneration, re-
stores goblet cells and mucus production and stimulates 
the production of AMP  [41] . Consistent with these obser-
vations, IL-22 administration attenuated disease severity 
in the DSS and T-cell receptor-    –/–   colitis models   [41] . 
Furthermore, an IL-23-dependent innate source of IL-22 
was shown to be critical for early immunity to the attach-
ing/effacing mouse intestinal bacterial pathogen   Citro-
bacter rodentium,   and recent data suggest that this pro-
tective IL-22 is derived from ROR   t +   Thy1 +   ILC   [42] . 
Conversely, clinical evidence suggests that IL-22 may be 
playing a pathogenic role in IBD, as patients with active 
CD have elevated levels of IL-22 detectable in the serum, 
and levels of IL-22 correlate with disease severity and IL-
23R genotype   [2]  . However, whether elevated IL-22 is 
driving disease progression or reflects a failed attempt at 
promoting resolution remains unclear. Harrison/Maloy
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  Thus, IL-23 can modulate the activation of a variety of 
innate and adaptive immune cells in the gut, which are 
mirrored by the diverse range of cytokine responses that 
are induced by IL-23. Under steady state conditions, these 
responses may play a critical role in the maintenance of 
epithelial barrier integrity and innate immune defence. 
However, sustained activation of IL-23-driven effector 
pathways may underlie the chronic immune pathology 
found in IBD (  fig. 1  b).
  Conclusions 
 The data summarized in this review highlight that in-
nate immune activation is a fundamental process that 
impacts on intestinal homeostasis on several levels ( fig. 2 ). 
It occurs not only in haematopoietic cells, but also in pa-
renchymal cells such as IEC. Constitutive tonic sensing 
of microbial factors by PRR in IEC and in innate leuco-
cytes stimulates tissue-protective innate defences that 
inhibit colonization and invasion by pathogens. In the 
steady state, myeloid cells control circuits that prevent 
harmful immune responses towards that intestinal mi-
crobiota. However, damage, stress or breach of the epithe-
lium activates a plethora of innate immune mechanisms 
and downstream inflammatory responses, and chronic 
a b e rran t  a cti va ti o n  o f  th es e  inn a t e  imm un e  p a th w a ys  
may play a key role in the characteristic pathology found 
in IBD patients. The activities of individual factors pro-
duced by innate immune cells in the gut, such as cyto-
kines, may be largely determined by their location, kinet-
ics and the presence of additional factors that can modu-
late their activity. Therefore, selective modulation of 
innate immune activation and of downstream mediators 
presents an ongoing challenge to effectively target delete-
rious inflammatory responses in IBD whilst sparing 
host-protective immunity in the intestinal tissues.
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Level of innate immune activation   Fig. 2.  Balanced innate immune activation 
maintains intestinal homeostasis. In the 
healthy intestine, constitutive tonic activa-
t i o n  o f  i n n a t e  i m m u n e  p a th w a y s  m ai n -
tains epithelial barrier integrity and the 
production of innate immune factors in 
the epithelium. Deficiencies in innate 
pathways may predispose to infection or 
impair barrier function leading to in-
creased bacterial translocation that elic-
its inflammatory responses. Conversely, 
chronic hyper-activation of innate im-
mune pathways in lamina propria leuco-
cytes plays a key role in sustaining patho-
logical inflammatory responses in the gut. 
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